



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

December 2019





© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

**BC Centre for Excellence in HIV/AIDS
Drug Treatment Program**

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8202
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

December 2019

N = 7356



Health Authority	Male	Female	All
FRASER	1438	431	1869
INTERIOR	408	101	509
NORTHERN	132	83	215
VANCOUVER COASTAL	3335	450	3785
VANCOUVER ISLAND	782	162	944
	6095	1227	7322
		Unknown/not stated:	34
		Total:	7356

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2014 - December 2019)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (December 2014 - December 2019)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (December 2014 - December 2019)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (December 2014 - December 2019)






1.6 Percent Distribution of Active Participants by CD4 Count (December 2014 - December 2019)






1.7 Percent Distribution of Inactive Participants by CD4 Count (December 2014 - December 2019)






1.8 Active and Inactive Participants (December 2014 - December 2019)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (December 2014 - December 2019)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (December 2014 - December 2019)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(December 2014 - December 2019)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (December 2014 - December 2019)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(December 2014 - December 2019)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (December 2014 - December 2019)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(December 2014 - December 2019)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (December 2014 - December 2019)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(December 2014 - December 2019)






1.18 Baseline CD4 for Antiretroviral First Starts
(December 2014 - December 2019)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(December 2014 - December 2019)**






1.20 Cumulative Resistance Testing Results by Resistance Category (December 2014 - December 2019)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (December 2014 - December 2019)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2019
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	27	5	0	5	2	590	5	<40	3
1988	29	6	0	6	4	345	6	<40	3
1989	27	52	1	53	41	530	52	<40	3
1990	25	54	0	54	33	480	53	<40	3
1991	26	37	3	40	23	480	38	<40	3
1992	25	60	5	65	43	530	63	<40	3
1993	24	134	14	148	125	540	145	<40	3
1994	23	79	13	92	69	530	90	<40	3
1995	23	129	21	150	115	580	145	<40	3
1996	21	336	55	391	288	575	369	<40	3
1997	19	273	34	307	232	620	281	<40	3
1998	18	191	42	233	176	570	224	<40	3
1999	18	160	38	198	147	580	187	<40	3
2000	18	120	34	154	122	585	150	<40	3
2001	18	120	30	150	113	590	142	<40	3
2002	17	123	26	149	113	600	140	<40	3
2003	16	152	30	182	133	560	177	<40	3
2004	15	157	40	197	154	560	189	<40	3
2005	14	184	45	229	182	630	218	<40	3
2006	13	188	38	226	177	590	216	<40	3
2007	12	252	50	302	233	620	277	<40	3
2008	11	276	65	341	267	630	318	<40	3
2009	10	308	68	376	283	660	346	<40	3
2010	9	274	71	345	268	630	323	<40	3
2011	8	329	73	402	310	680	368	<40	3
2012	7	262	64	326	245	700	297	<40	3
2013	6	272	64	336	247	660	303	<40	3
2014	5	289	54	343	244	715	310	<40	3
2015	4	288	49	337	260	685	317	<40	3
2016	3	283	57	340	246	654	311	<40	3
2017	3	233	37	270	222	668	256	<40	3
2018	1	213	56	269	211	649	255	<40	3
2019	1	263	52	315	272	610	305	<40	3
Total:		6102	1229	7331					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	7281	750	2385	<40	2110	610
FEB-2018	7245	762	1904	<40	1744	610
MAR-2018	7270	769	2050	<40	1831	617
APR-2018	7256	776	2080	<40	1841	620
MAY-2018	7273	772	2147	<40	1928	600
JUN-2018	7273	786	2002	<40	1786	610
JUL-2018	7283	784	2037	<40	1810	600
AUG-2018	7288	794	2092	<40	1874	620
SEP-2018	7244	794	2015	<40	1787	620
OCT-2018	7338	773	2170	<40	1945	610
NOV-2018	7341	780	2091	<40	1814	630
DEC-2018	7358	785	1747	<40	1536	620
JAN-2019	7398	792	2456	<40	2144	610
FEB-2019	7379	799	1854	<40	1581	620
MAR-2019	7417	790	2086	<40	1753	610
APR-2019	7374	793	2143	<40	1748	610
MAY-2019	7434	792	2127	<40	1762	620
JUN-2019	7384	803	1928	<40	1593	620
JUL-2019	7392	807	2112	<40	1690	620
AUG-2019	7380	810	2109	<40	1618	607
SEP-2019	7361	806	2015	<40	1558	600
OCT-2019	7420	786	2141	<40	1709	620
NOV-2019	7366	781	2030	<40	1509	630
DEC-2019	7356	782	1698	<40	1182	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2018	1429	3300	79	890	71	380
FEB-2018	1473	3111	79	1036	66	440
MAR-2018	1457	3197	75	59	70	485
APR-2018	1474	3163	73	459	63	497
MAY-2018	1463	3228	93	<40	82	455
JUN-2018	1473	3226	74	1260	70	440
JUL-2018	1473	3257	70	<40	55	570
AUG-2018	1502	3163	64	63	60	485
SEP-2018	1546	2985	87	259	81	410
OCT-2018	1473	3335	79	<50	69	350
NOV-2018	1485	3311	82	87	74	480
DEC-2018	1481	3343	57	355	48	470
JAN-2019	1458	3450	73	73	65	350
FEB-2019	1488	3376	75	108	66	590
MAR-2019	1453	3532	73	729	60	400
APR-2019	1490	3429	80	<50	70	490
MAY-2019	1437	3671	78	87	68	455
JUN-2019	1491	3475	77	<40	69	510
JUL-2019	1481	3533	70	<40	57	530
AUG-2019	1504	3474	78	50	65	510
SEP-2019	1531	3358	92	<40	73	580
OCT-2019	1469	3673	80	120	67	470
NOV-2019	1490	3628	65	<40	51	560
DEC-2019	1486	3663	59	<40	48	490

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs)

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2018	7242	1429	12	12	193	127	56	13218
FEB-2018	7211	1473	11	27	125	169	-31	13255
MAR-2018	7230	1457	17	21	158	138	19	13282
APR-2018	7223	1474	12	15	154	160	-7	13304
MAY-2018	7243	1463	9	12	173	153	20	13329
JUN-2018	7239	1473	13	16	152	156	-4	13351
JUL-2018	7241	1473	13	13	165	155	2	13377
AUG-2018	7252	1502	9	27	158	159	11	13416
SEP-2018	7207	1546	14	15	155	194	-45	13442
OCT-2018	7306	1473	8	19	218	126	99	13478
NOV-2018	7314	1485	5	9	171	164	8	13504
DEC-2018	7330	1481	11	19	152	142	16	13529
JAN-2019	7365	1458	14	20	191	159	35	13564
FEB-2019	7351	1488	7	16	160	180	-14	13593
MAR-2019	7376	1453	15	13	187	147	25	13613
APR-2019	7332	1490	10	15	151	179	-44	13641
MAY-2019	7396	1437	11	22	197	138	64	13684
JUN-2019	7344	1491	14	13	137	184	-52	13705
JUL-2019	7356	1481	13	13	178	163	12	13728
AUG-2019	7351	1504	12	18	167	175	-5	13764
SEP-2019	7330	1531	13	16	182	202	-21	13792
OCT-2019	7349	1469	3	13	221	145	19	13821
NOV-2019	7342	1490	9	17	158	164	-7	13854
DEC-2019	7331	1486	7	12	161	164	-11	13881

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





**2.5 Percent Distribution of Participants on ARV Therapy
by Number of Drugs**

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2018	60	6718	448	55	7281	0.82%	92.27%	6.15%	0.76%	100.00%
FEB-2018	64	6672	450	59	7245	0.88%	92.09%	6.21%	0.81%	100.00%
MAR-2018	62	6699	453	56	7270	0.85%	92.15%	6.23%	0.77%	100.00%
APR-2018	62	6688	449	57	7256	0.85%	92.17%	6.19%	0.79%	100.00%
MAY-2018	69	6691	455	58	7273	0.95%	92.00%	6.26%	0.80%	100.00%
JUN-2018	62	6707	447	57	7273	0.85%	92.22%	6.15%	0.78%	100.00%
JUL-2018	53	6717	458	55	7283	0.73%	92.23%	6.29%	0.76%	100.00%
AUG-2018	56	6722	454	56	7288	0.77%	92.23%	6.23%	0.77%	100.00%
SEP-2018	55	6676	456	57	7244	0.76%	92.16%	6.29%	0.79%	100.00%
OCT-2018	54	6756	474	54	7338	0.74%	92.07%	6.46%	0.74%	100.00%
NOV-2018	53	6763	475	50	7341	0.72%	92.13%	6.47%	0.68%	100.00%
DEC-2018	52	6780	477	49	7358	0.71%	92.14%	6.48%	0.67%	100.00%
JAN-2019	54	6805	486	53	7398	0.73%	91.98%	6.57%	0.72%	100.00%
FEB-2019	52	6786	492	49	7379	0.70%	91.96%	6.67%	0.66%	100.00%
MAR-2019	59	6818	490	50	7417	0.80%	91.92%	6.61%	0.67%	100.00%
APR-2019	56	6780	490	48	7374	0.76%	91.94%	6.64%	0.65%	100.00%
MAY-2019	55	6842	492	45	7434	0.74%	92.04%	6.62%	0.61%	100.00%
JUN-2019	58	6797	481	48	7384	0.79%	92.05%	6.51%	0.65%	100.00%
JUL-2019	59	6793	492	48	7392	0.80%	91.90%	6.66%	0.65%	100.00%
AUG-2019	58	6787	485	50	7380	0.79%	91.96%	6.57%	0.68%	100.00%
SEP-2019	56	6767	486	52	7361	0.76%	91.93%	6.60%	0.71%	100.00%
OCT-2019	60	6819	488	53	7420	0.81%	91.90%	6.58%	0.71%	100.00%
NOV-2019	57	6773	486	50	7366	0.77%	91.95%	6.60%	0.68%	100.00%
DEC-2019	60	6767	480	49	7356	0.82%	91.99%	6.53%	0.67%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	10 36%	3314 47%	9 32%	3070 43%	1 4%	61 1%	0 0%	5 0%	0 0%	4 0%	2 7%	292 4%	16 57%	3628 51%
FEB-2018	13 35%	3315 47%	12 32%	3073 44%	0 0%	61 1%	0 0%	5 0%	0 0%	4 0%	0 0%	299 4%	25 68%	3578 51%
MAR-2018	10 37%	3334 47%	10 37%	3099 44%	0 0%	59 1%	0 0%	4 0%	0 0%	4 0%	0 0%	311 4%	17 63%	3563 50%
APR-2018	5 23%	3342 47%	5 23%	3111 44%	0 0%	55 1%	0 0%	3 0%	0 0%	4 0%	2 9%	333 5%	15 68%	3533 50%
MAY-2018	9 39%	3350 48%	8 35%	3124 44%	1 4%	57 1%	0 0%	5 0%	0 0%	4 0%	1 4%	351 5%	13 57%	3504 50%
JUN-2018	7 35%	3364 48%	7 35%	3141 45%	0 0%	53 1%	0 0%	5 0%	0 0%	3 0%	1 5%	379 5%	12 60%	3473 49%
JUL-2018	7 28%	3393 48%	7 28%	3171 45%	0 0%	51 1%	0 0%	5 0%	0 0%	3 0%	4 16%	398 6%	14 56%	3444 49%
AUG-2018	13 33%	3392 48%	14 36%	3180 45%	0 0%	50 1%	0 0%	4 0%	0 0%	3 0%	2 5%	415 6%	23 59%	3413 48%
SEP-2018	4 15%	3377 48%	3 12%	3162 45%	1 4%	47 1%	0 0%	4 0%	0 0%	2 0%	4 15%	446 6%	18 69%	3364 48%
OCT-2018	11 31%	3418 48%	9 26%	3205 45%	1 3%	49 1%	0 0%	3 0%	0 0%	2 0%	0 0%	479 7%	25 71%	3382 47%
NOV-2018	9 35%	3428 48%	8 31%	3214 45%	0 0%	47 1%	0 0%	4 0%	0 0%	2 0%	1 4%	491 7%	17 65%	3351 47%
DEC-2018	8 32%	3446 48%	8 32%	3233 45%	0 0%	45 1%	0 0%	4 0%	0 0%	1 0%	2 8%	504 7%	15 60%	3348 47%
JAN-2019	8 23%	3471 48%	7 20%	3258 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3360 47%
FEB-2019	13 45%	3464 48%	12 41%	3263 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	542 8%	13 45%	3310 46%
MAR-2019	6 30%	3477 48%	6 30%	3280 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3310 46%
APR-2019	12 43%	3478 48%	12 43%	3286 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3253 45%
MAY-2019	14 33%	3510 49%	14 33%	3318 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	24 57%	3266 45%
JUN-2019	3 14%	3491 49%	3 14%	3303 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	610 8%	16 76%	3210 45%
JUL-2019	8 35%	3514 49%	8 35%	3333 46%	0 0%	39 1%	0 0%	2 0%	0 0%	1 0%	1 4%	626 9%	14 61%	3191 44%
AUG-2019	14 39%	3519 49%	12 33%	3344 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	632 9%	20 56%	3155 44%
SEP-2019	6 21%	3500 49%	6 21%	3324 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 18%	657 9%	17 61%	3135 44%
OCT-2019	4 14%	3522 49%	2 7%	3341 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	672 9%	23 82%	3159 44%
NOV-2019	8 24%	3465 48%	7 21%	3289 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	731 10%	19 58%	3131 44%
DEC-2019	1 4%	3443 48%	1 4%	3266 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	14 52%	858 12%	12 44%	3061 43%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2018	18	64%	3704	52%
FEB-2018	24	65%	3672	52%
MAR-2018	17	63%	3669	52%
APR-2018	17	77%	3655	52%
MAY-2018	14	61%	3650	52%
JUN-2018	13	65%	3650	52%
JUL-2018	18	72%	3647	52%
AUG-2018	25	64%	3646	52%
SEP-2018	22	85%	3624	51%
OCT-2018	24	69%	3683	52%
NOV-2018	17	65%	3667	51%
DEC-2018	17	68%	3669	51%
JAN-2019	27	77%	3699	51%
FEB-2019	16	55%	3679	51%
MAR-2019	14	70%	3706	51%
APR-2019	16	57%	3669	51%
MAY-2019	28	67%	3695	51%
JUN-2019	18	86%	3657	51%
JUL-2019	15	65%	3665	51%
AUG-2019	22	61%	3639	51%
SEP-2019	22	79%	3639	51%
OCT-2019	24	86%	3685	51%
NOV-2019	25	76%	3689	51%
DEC-2019	26	96%	3722	52%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	8 0%	3 30%	1313 45%	7 70%	1414 48%	0 0%	195 7%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
FEB-2018	0 0%	6 0%	0 0%	1255 44%	15 100%	1420 49%	0 0%	189 7%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAR-2018	0 0%	7 0%	1 9%	1243 43%	10 91%	1438 50%	0 0%	187 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
APR-2018	0 0%	6 0%	0 0%	1220 43%	11 100%	1435 50%	0 0%	180 6%	0 0%	2 0%	0 0%	1 0%	0 0%	11 0%
MAY-2018	0 0%	7 0%	0 0%	1204 42%	5 100%	1438 51%	0 0%	181 6%	0 0%	2 0%	0 0%	1 0%	0 0%	10 0%
JUN-2018	0 0%	7 0%	1 8%	1185 42%	11 92%	1428 51%	0 0%	175 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
JUL-2018	0 0%	7 0%	2 20%	1168 42%	7 70%	1438 52%	1 10%	168 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
AUG-2018	0 0%	7 0%	5 31%	1155 42%	11 69%	1422 52%	0 0%	166 6%	0 0%	1 0%	0 0%	1 0%	0 0%	8 0%
SEP-2018	0 0%	7 0%	1 14%	1132 42%	6 86%	1404 52%	0 0%	159 6%	0 0%	1 0%	0 0%	1 0%	0 0%	10 0%
OCT-2018	0 0%	7 0%	3 17%	1121 41%	15 83%	1445 53%	0 0%	153 6%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
NOV-2018	0 0%	6 0%	1 14%	1116 41%	6 86%	1456 53%	0 0%	146 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
DEC-2018	0 0%	5 0%	1 11%	1106 41%	7 78%	1457 54%	1 11%	145 5%	0 0%	0 0%	0 0%	2 0%	0 0%	9 0%
JAN-2019	0 0%	6 0%	1 8%	1098 40%	11 92%	1478 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1071 40%	9 82%	1475 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1487 55%	0 0%	133 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1028 39%	7 70%	1479 56%	2 20%	133 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1034 39%	11 92%	1481 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1004 39%	9 100%	1468 57%	0 0%	120 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	984 38%	7 100%	1487 57%	0 0%	113 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	971 38%	11 92%	1463 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	956 37%	12 92%	1486 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	961 37%	13 93%	1497 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	942 37%	3 100%	1477 58%	0 0%	102 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	927 37%	6 100%	1469 59%	0 0%	99 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2018	0	0%	1	0%
FEB-2018	0	0%	1	0%
MAR-2018	0	0%	1	0%
APR-2018	0	0%	1	0%
MAY-2018	0	0%	1	0%
JUN-2018	0	0%	1	0%
JUL-2018	0	0%	1	0%
AUG-2018	0	0%	1	0%
SEP-2018	0	0%	1	0%
OCT-2018	0	0%	1	0%
NOV-2018	0	0%	1	0%
DEC-2018	0	0%	1	0%
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	3 50%	778 37%	1 17%	262 12%	2 33%	757 36%	0 0%	302 14%
FEB-2018	0 0%	0 0%	3 75%	769 37%	0 0%	257 12%	0 0%	749 36%	1 25%	306 15%
MAR-2018	0 0%	0 0%	1 33%	757 37%	0 0%	250 12%	0 0%	736 36%	2 67%	311 15%
APR-2018	0 0%	0 0%	1 50%	745 37%	0 0%	245 12%	0 0%	731 36%	1 50%	318 16%
MAY-2018	0 0%	0 0%	4 67%	725 36%	1 17%	252 12%	0 0%	727 36%	1 17%	316 16%
JUN-2018	0 0%	0 0%	1 50%	720 36%	0 0%	248 12%	0 0%	724 36%	1 50%	313 16%
JUL-2018	0 0%	0 0%	3 60%	721 36%	0 0%	243 12%	0 0%	717 36%	2 40%	313 16%
AUG-2018	0 0%	0 0%	2 100%	714 36%	0 0%	238 12%	0 0%	716 36%	0 0%	308 16%
SEP-2018	0 0%	0 0%	6 100%	706 36%	0 0%	236 12%	0 0%	712 36%	0 0%	311 16%
OCT-2018	0 0%	0 0%	3 60%	696 36%	0 0%	234 12%	0 0%	710 36%	2 40%	323 16%
NOV-2018	0 0%	0 0%	8 80%	687 35%	0 0%	230 12%	0 0%	700 36%	2 20%	322 17%
DEC-2018	0 0%	0 0%	1 100%	684 36%	0 0%	225 12%	0 0%	696 36%	0 0%	319 17%
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	668 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	224 12%	1 25%	681 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	646 35%	0 0%	223 12%	0 0%	678 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	6 100%	648 35%	0 0%	219 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	636 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	636 35%	0 0%	211 12%	0 0%	657 36%	0 0%	323 18%
AUG-2019	0 0%	1 0%	2 100%	626 35%	0 0%	207 11%	0 0%	647 36%	0 0%	327 18%
SEP-2019	0 0%	1 0%	4 80%	613 35%	0 0%	209 12%	0 0%	623 35%	1 20%	325 18%
OCT-2019	0 0%	1 0%	6 60%	615 35%	1 10%	211 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	615 37%	0 0%	209 12%	1 14%	525 31%	1 14%	326 19%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	204 12%	0 0%	513 31%	0 0%	325 20%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2018	0 0%	0 0%	9 47%	2003 60%	8 42%	630 19%	0 0%	46 1%	2 11%	685 21%
FEB-2018	0 0%	0 0%	16 70%	2023 60%	6 26%	640 19%	0 0%	45 1%	1 4%	675 20%
MAR-2018	0 0%	0 0%	14 100%	2058 61%	0 0%	645 19%	0 0%	43 1%	0 0%	674 20%
APR-2018	0 0%	0 0%	8 67%	2102 61%	4 33%	653 19%	0 0%	44 1%	0 0%	681 20%
MAY-2018	0 0%	0 0%	13 65%	2135 61%	4 20%	664 19%	1 5%	42 1%	3 15%	675 19%
JUN-2018	0 0%	0 0%	8 73%	2167 61%	2 18%	672 19%	0 0%	42 1%	1 9%	676 19%
JUL-2018	0 0%	0 0%	7 58%	2201 62%	4 33%	674 19%	0 0%	42 1%	1 8%	675 19%
AUG-2018	0 0%	0 0%	23 79%	2251 62%	5 17%	675 19%	0 0%	42 1%	1 3%	671 19%
SEP-2018	0 0%	9 0%	5 36%	2261 62%	9 64%	689 19%	0 0%	41 1%	0 0%	655 18%
OCT-2018	0 0%	17 0%	13 76%	2318 63%	4 24%	708 19%	0 0%	40 1%	0 0%	658 18%
NOV-2018	0 0%	17 0%	11 100%	2344 63%	0 0%	703 19%	0 0%	38 1%	0 0%	650 17%
DEC-2018	0 0%	17 0%	13 76%	2367 63%	4 24%	719 19%	0 0%	39 1%	0 0%	652 17%
JAN-2019	0 0%	16 0%	15 75%	2430 63%	4 20%	730 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2436 63%	5 23%	727 19%	0 0%	40 1%	1 5%	653 17%
MAR-2019	0 0%	27 1%	8 62%	2484 64%	5 38%	747 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2501 64%	3 21%	739 19%	0 0%	36 1%	3 21%	637 16%
MAY-2019	0 0%	27 1%	19 68%	2566 64%	6 21%	748 19%	0 0%	37 1%	3 11%	636 16%
JUN-2019	0 0%	27 1%	10 77%	2567 65%	3 23%	746 19%	0 0%	37 1%	0 0%	625 16%
JUL-2019	0 0%	27 1%	14 82%	2611 65%	3 18%	758 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2651 65%	1 4%	756 19%	0 0%	36 1%	3 11%	627 15%
SEP-2019	0 0%	28 1%	8 50%	2656 65%	6 38%	758 19%	0 0%	37 1%	2 13%	630 15%
OCT-2019	0 0%	28 1%	13 87%	2730 66%	1 7%	761 18%	0 0%	34 1%	1 7%	631 15%
NOV-2019	3 13%	88 2%	16 70%	2750 65%	4 17%	774 18%	0 0%	33 1%	0 0%	623 15%
DEC-2019	13 65%	233 5%	6 30%	2727 64%	1 5%	744 17%	0 0%	33 1%	0 0%	606 14%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2018	2004	27.52	1644	22.58	2592	35.60	117	1.61	55	0.76	869	11.94
FEB-2018	1961	27.07	1629	22.48	2610	36.02	116	1.60	59	0.81	870	12.01
MAR-2018	1974	27.15	1615	22.21	2644	36.37	113	1.55	56	0.77	868	11.94
APR-2018	1928	26.57	1596	22.00	2696	37.16	114	1.57	57	0.79	865	11.92
MAY-2018	1918	26.37	1575	21.66	2732	37.56	114	1.57	58	0.80	876	12.04
JUN-2018	1903	26.17	1562	21.48	2784	38.28	113	1.55	57	0.78	854	11.74
JUL-2018	1886	25.90	1565	21.49	2813	38.62	110	1.51	55	0.76	854	11.73
AUG-2018	1860	25.52	1549	21.25	2859	39.23	111	1.52	56	0.77	853	11.70
SEP-2018	1823	25.17	1532	21.15	2878	39.73	109	1.50	57	0.79	845	11.66
OCT-2018	1848	25.18	1529	20.84	2946	40.15	104	1.42	54	0.74	857	11.68
NOV-2018	1842	25.09	1522	20.73	2966	40.40	106	1.44	50	0.68	855	11.65
DEC-2018	1835	24.94	1510	20.52	3005	40.84	104	1.41	49	0.67	855	11.62
JAN-2019	1833	24.78	1481	20.02	3063	41.40	100	1.35	53	0.72	868	11.73
FEB-2019	1805	24.46	1479	20.04	3079	41.73	99	1.34	49	0.66	868	11.76
MAR-2019	1795	24.20	1473	19.86	3131	42.21	98	1.32	50	0.67	870	11.73
APR-2019	1762	23.89	1461	19.81	3146	42.66	100	1.36	48	0.65	857	11.62
MAY-2019	1774	23.86	1450	19.50	3210	43.18	97	1.30	45	0.61	858	11.54
JUN-2019	1746	23.65	1441	19.52	3210	43.47	95	1.29	48	0.65	844	11.43
JUL-2019	1719	23.25	1430	19.35	3246	43.91	92	1.24	48	0.65	857	11.59
AUG-2019	1691	22.91	1404	19.02	3299	44.70	94	1.27	50	0.68	842	11.41
SEP-2019	1702	23.12	1368	18.58	3307	44.93	93	1.26	52	0.71	839	11.40
OCT-2019	1710	23.05	1346	18.14	3371	45.43	93	1.25	53	0.71	847	11.42
NOV-2019	1675	22.74	1275	17.31	3438	46.67	91	1.24	50	0.68	837	11.36
DEC-2019	1644	22.35	1249	16.98	3493	47.49	92	1.25	49	0.67	829	11.27

Definitions:

n is number of participants on the specified regimen class in the specified month
 % is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2018	12	1	1	0	4	4	470
FEB-2018	27	3	2	2	6	13	485
MAR-2018	21	4	1	5	4	6	325
APR-2018	15	0	0	5	3	5	480
MAY-2018	12	1	0	4	3	2	370
JUN-2018	16	3	5	1	1	6	237
JUL-2018	13	4	1	3	4	1	284
AUG-2018	27	2	2	6	4	13	450
SEP-2018	15	2	3	1	3	5	405
OCT-2018	19	0	1	2	5	10	525
NOV-2018	9	2	2	2	0	2	185
DEC-2018	19	2	0	5	5	7	380
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	22	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	16	0	0	2	4	8	535
OCT-2019	13	1	1	3	4	3	415
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	1	5	2	4	350

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2018	11954	3650
FEB-2018	11984	3665
MAR-2018	12011	3694
APR-2018	12043	3724
MAY-2018	12078	3749
JUN-2018	12090	3752
JUL-2018	12116	3776
AUG-2018	12130	3771
SEP-2018	12153	3792
OCT-2018	12172	3792
NOV-2018	12209	3811
DEC-2018	12213	3806
JAN-2019	12253	3831
FEB-2019	12261	3830
MAR-2019	12291	3860
APR-2019	12318	3884
MAY-2019	12334	3885
JUN-2019	12334	3890
JUL-2019	12351	3905
AUG-2019	12383	3922
SEP-2019	12403	3939
OCT-2019	12437	3963
NOV-2019	12460	3972
DEC-2019	12486	3988

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
December 2019

N = 7356

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2019

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



KELOWNA BY POSTAL CODE







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2019

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2019

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2019

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

December 2019

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





**4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
INTERIOR Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	9	10	*
	50+	28	40	*
	Total HSDA:	43	56	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	73	97	54	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	365	495	280	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	0
	20-34	*	*	13
	35-49	*	*	53
	50+	*	*	81
Total HSDA:	191	262	147	
Total HA:		672	910	509

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	5	5	*
	20-34	63	64	*
	35-49	176	197	*
	50+	428	644	*
Total HA:		672	910	509

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	538	729	408
Female	134	181	101

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	509	55	610	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	18	11
	5 years or more	12	5
	<5 years	13	12
	Total HSDA:	43	28
KOOTENAY BOUNDARY	10 years or more	45	32
	5 years or more	15	11
	<5 years	13	11
	Total HSDA:	73	54
OKANAGAN	10 years or more	226	163
	5 years or more	68	57
	<5 years	71	60
	Total HSDA:	365	280
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	105	75
	5 years or more	43	37
	<5 years	43	35
	Total HSDA:	191	147
Total HA:		672	509

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	394	281
5 years or more	138	110
<5 years	140	118
Total HA:	672	509

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	42	64	11	26
KOOTENAY BOUNDARY	71	122	21	44
OKANAGAN	214	925	53	288
THOMPSON/CARIBOO/SHUSWAP	133	513	34	136
Total:	460	1624	119	494

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	91

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	29	31	23
	35-49	104	114	77
	50+	237	311	183
	Total HSDA:		377	463
FRASER NORTH	0-19	8	8	*
	20-34	113	114	*
	35-49	347	376	*
	50+	560	885	*
	Total HSDA:		1028	1383
FRASER SOUTH	0-19	7	7	*
	20-34	118	120	*
	35-49	325	370	*
	50+	551	808	*
	Total HSDA:		1001	1305
Total HA:		2406	3151	1869

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	12
	20-34	260	265	191
	35-49	776	860	603
	50+	1348	2004	1063
Total HA:		2406	3151	1869

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1830	2417	1438
Female	576	734	431

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1869	52	634	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
FRASER Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	222	167
	5 years or more	72	60
	<5 years	83	62
	Total HSDA:	377	289
FRASER NORTH	10 years or more	572	402
	5 years or more	250	196
	<5 years	206	173
	Total HSDA:	1028	771
FRASER SOUTH	10 years or more	553	436
	5 years or more	229	177
	<5 years	219	196
	Total HSDA:	1001	809
Total HA:		2406	1869

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1347	1005
	5 years or more	551	433
	<5 years	508	431
Total HA:		2406	1869

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	140	495	29	60
FRASER NORTH	249	1570	47	232
FRASER SOUTH	214	1478	45	466
Total:	603	3543	121	758

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	200
FRASER NORTH	645
FRASER SOUTH	503
Total:	1348

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	0
	20-34	*	*	21
	35-49	*	*	65
	50+	*	*	203
	Total HSDA:		346	493
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		174	223
VANCOUVER	0-19	26	26	7
	20-34	444	458	313
	35-49	1367	1541	980
	50+	2827	4830	2066
	Total HSDA:	4664	6855	3366
Total HA:		5184	7571	3785

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	29	29	8
	20-34	497	512	351
	35-49	1493	1679	1078
	50+	3165	5351	2348
Total HA:		5184	7571	3785

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4575	6646	3335
Female	607	923	450

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3785	53	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	188	150
	5 years or more	88	76
	<5 years	70	63
	Total HSDA:	346	289
RICHMOND	10 years or more	102	71
	5 years or more	35	28
	<5 years	37	31
	Total HSDA:	174	130
VANCOUVER	10 years or more	2781	1929
	5 years or more	1131	812
	<5 years	752	625
	Total HSDA:	4664	3366
Total HA:		5184	3785

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3071	2150
	5 years or more	1254	916
	<5 years	859	719
Total HA:		5184	3785

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	170	496	51	176
RICHMOND	44	288	12	94
VANCOUVER	599	10844	194	5278
Total:	813	11628	257	5548

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	8
RICHMOND	6
VANCOUVER	109
Total:	123

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		329	464
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		126	168
SOUTH VANCOUVER ISLAND	0-19	*	*	0
	20-34	*	*	55
	35-49	*	*	142
	50+	*	*	376
	Total HSDA:		741	1047
Total HA:		1196	1679	944

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1196	1679	944

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	987	1383	782
Female	209	296	162

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	944	54	560	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	181	147
	5 years or more	70	57
	<5 years	78	62
	Total HSDA:	329	266
NORTH VANCOUVER ISLAND	10 years or more	73	60
	5 years or more	33	27
	<5 years	20	18
	Total HSDA:	126	105
SOUTH VANCOUVER ISLAND	10 years or more	433	315
	5 years or more	158	136
	<5 years	150	122
	Total HSDA:	741	573
Total HA:		1196	944

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	687	522
	5 years or more	261	220
	<5 years	248	202
Total HA:		1196	944

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	192	866	75	201
NORTH VANCOUVER ISLAND	137	268	45	81
SOUTH VANCOUVER ISLAND	211	1791	43	555
Total:	540	2925	163	837

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	51
NORTH VANCOUVER ISLAND	41
SOUTH VANCOUVER ISLAND	111
Total:	203

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		40	48
NORTH WEST	20-34	11	12	5
	35-49	16	32	13
	50+	41	63	34
	Total HSDA:	68	107	52
NORTHERN INTERIOR	0-19	5	5	*
	20-34	25	26	*
	35-49	70	89	*
	50+	91	152	*
	Total HSDA:	191	272	138
Total HA:		299	427	215

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	39	41	*
	35-49	104	142	*
	50+	150	238	*
Total HA:		299	427	215

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	180	263	132
Female	119	164	83

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	215	50	550	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	20	11
	5 years or more	13	9
	<5 years	7	5
	Total HSDA:	40	25
NORTH WEST	10 years or more	35	25
	5 years or more	20	17
	<5 years	13	10
	Total HSDA:	68	52
NORTHERN INTERIOR	10 years or more	76	54
	5 years or more	63	49
	<5 years	52	35
	Total HSDA:	191	138
Total HA:		299	215

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	131	90
	5 years or more	96	75
	<5 years	72	50
Total HA:		299	215

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	39	63	6	8
NORTH WEST	72	162	14	30
NORTHERN INTERIOR	105	466	13	180
Total:	216	691	33	218

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	6
NORTH WEST	20
NORTHERN INTERIOR	14
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	22	38	13
	THOMPSON/CARIBOO/SHUSWAP	25	46	20
	Total HA:	59	103	44
FRASER	FRASER EAST	42	52	33
	FRASER NORTH	54	90	44
	FRASER SOUTH	74	107	54
	Total HA:	170	249	131
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	28	51	26
	RICHMOND	9	14	6
	VANCOUVER	483	855	383
	Total HA:	520	920	415
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	80	43
	NORTH VANCOUVER ISLAND	18	27	16
	SOUTH VANCOUVER ISLAND	38	81	31
	Total HA:	107	188	90
NORTHERN	NORTH EAST	10	12	9
	NORTH WEST	27	57	20
	NORTHERN INTERIOR	73	110	59
	Total HA:	110	179	88
Total:		966	1639	768

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	605	1043	477
Female	361	596	291

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	768	51	480	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

